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The NHMRC Clinical Trials Centre at the University of Sydney conducts 
investigator-initiated clinical trials with national and international 
collaborators, and contributes expertise to trials run by others. It also:
•	 takes a lead in proposing new directions for clinical research in 
Australia, particularly research aligned with national policy and 
clinical practice
•	 participates in translational research, from bench to bedside
•	 conducts methodological research in relation to clinical trials
•	 reviews and synthesises evidence from completed trials,  
and is at the forefront of developments in methods,  
such as prospective meta-analysis
•	 supervises postgraduate students in all of these areas
•	 offers postgraduate degrees in clinical trials research
•	 runs short courses to train people for Australian medical research.
•	 undertakes health technology and diagnostic test assessments, 
economic analyses, biostatistical design and analysis, and 
automated central randomisation services.
Core funding is provided by the NHMRC, and specific projects  
are funded by government, public and private institutions  
and the pharmaceutical industry. 
The CTC is at two sites in Camperdown in inner Sydney —  
the Medical Foundation Building on Parramatta Road and  
Chris O’Brien Lifehouse on Missenden Road.
This report describes highlights of the CTC’s achievements for 2015. 
Since 1998,  
the CTC has been 
initiating, leading, 
conducting, analysing 
and  publishing 
collaborative trials 
and related research, 
with the aim of 
improving health 
outcomes in Australia 
and internationally.
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Directors’ report 
The CTC, over the past 28 years, 
has been helping improve health in 
Australia and elsewhere by advancing 
clinical trial research. We do this, with 
our collaborators, through designing 
and conducting trials for public 
good, interpreting and combining 
results from other trials and studies 
worldwide, and conducting associated 
research that maximises the scientific 
value of these efforts.
Major achievements in 2015 have 
included significant findings in several 
areas of health care, especially in 
oncology, diabetes, cardiovascular 
disease and neonatology; 
biomarker discovery; advances in 
trial methodology; integrating 
evidence from trials; leadership of the 
international symposium; and strong 
growth in grants and publications.
Over this decade we have seen a 
transformational change in clinical 
trials. In some settings, trials have 
become smaller, with defined 
subpopulations for targeted therapies, 
and the increasing use of adaptive 
methods, molecular profiling 
and surrogate endpoints. These 
developments are continuing, but 
large-scale trials are also still needed 
in areas where moderate treatment 
effects in broader populations can 
lead to substantial public health 
benefit. CTC, with its strength in 
clinical research methodology, is well 
placed to develop ways of meeting 
the associated challenges and provide 
reliable, valid and relevant results.
A key tenet of our research direction 
is the need to make clinical research 
a more integral part of health care, 
for the benefit of practice, research, 
and health care expenditure. This 
means a paradigm shift that captures 
effort and goodwill across the whole 
health system, including clinical trial 
networks and centres developing 
trials in areas of need, with generic 
infrastructure and intellectual 
underpinning for conducting them.
CTC has been very supportive in 
the formation, development and 
activities of the Australian Clinical 
Trials Alliance. ACTA is a means 
for triallists across all disciplines 
and across the full range of disease 
areas to work together, and with 
governments, to generate scientific 
evidence for new and existing health 
care treatments most efficiently 
and at the lowest cost. The highly 
successful ACTA symposium in 
October brought together new 
ideas and challenges and opened 
them to debate and development. 
These include global trends towards 
embedding clinical trials in clinical 
care, challenges in trial design and 
conduct, maximising the value of 
clinical registries, and improving 
public awareness and consumer 
involvement in clinical research. The 
symposium attracted over 500 people 
attending from all over Australia and 
elsewhere, including a faculty of 45 
international and national speakers.
Working with individuals and groups 
with diverse perspectives allows 
us to achieve better and more 
relevant results. Patients, carers and 
supporters have long been part of 
the clinical trials program—through 
consumer advisory panels and 
associated groups. This is an area 
that we see as important and that 
has been growing. In our neonatal 
studies, for example, parent groups 
are closely involved as full partners in 
the collaborative research process.
Increasingly, Australian trials are 
registered on the Australian New 
Zealand Clinical Trials Registry. 
The registry supports research 
transparency by making current trials 
public. We recently used data from the 
registry to quantify current research in 
relation to government-established 
health priority areas, which are based 
on the burden of the disease. This 
showed that some disease areas,  
such as obesity and dementia, may be 
under-researched, and also that larger 
trials or planned meta-analyses of 
smaller ones are needed if Australian 
health care is to be based on the most 
robust available evidence.
Our oncology trials continue to 
generate new evidence for practice.  
A La CaRT, an AGITG-RACS-CSSANZ-
CTC study, which was one of the 
largest trials of complex surgery 
ever conducted, reported on the 
current value of laparoscopic surgery, 
compared with open surgery, for 
rectal cancer. The international 
Symptom Benefit study explored 
how we measure the benefit of 
chemotherapy, and led to worldwide 
reflection on use of palliative 
chemotherapy for marginal benefits.
Especially in its close ties with 
Sydney Catalyst, CTC’s oncology 
researchers are embracing the full 
research pathway, in which clinical 
trials in their various phases are the 
link between laboratory discoveries 
and treatment protocols. Trials more 
often include thorough genetic and 
molecular typing as a condition of 
enrolment. In this way, treatment is 
tailored to the individual patient, with 
greater chance that the treatment will 
be successful.
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In the area of cardiovascular disease, 
the CTC’s early landmark trial, LIPID,  
is still a source of active research: 
in the laboratory exploration of 
potential biomarkers of cardiovascular 
risk; and in international meta-
analysis of data on statins, which is 
guiding treatment of cardiovascular 
diseases. Similarly, the FIELD trial, 
with nearly 10,000 patients with 
adult diabetes, was completed many 
years ago, but opened a door to 
new insights into vascular disease 
in diabetes, where several exciting 
laboratory investigations  
are continuing.
In other initiatives, our diabetes  
group have approached the 
worldwide scourge of diabetes from 
several different directions: including 
type 1 diabetes trials and novel 
trials in remote areas; advocacy 
initiatives; and extensive laboratory 
studies on mechanisms of treatment 
and risk. For example, the 12-year 
study showing that undernutrition 
over generations caused epigenetic 
changes in rats was an illustrated 
cover story in Cell Metabolism.
Major new trials in perinatal and 
neonatal medicine were launched 
in 2015. These trials require large 
numbers of infants, the goodwill and 
trust of parents and a high degree of 
organisation and motivation from the 
investigators and staff. CTC’s neonatal 
group focuses on improving the 
prospects of newborn infants at risk, 
while also seeking better ways  
of conducting trials in this area.
Two senior academics joined CTC in 
2015. Professor Philip Hogg became 
Chair Translational Cancer Research 
at CTC and head and Professor of 
Translational Cancer Research for 
Sydney Catalyst. We also appointed 
a new health economics director, 
Associate Professor Rachael Morton. 
Her group adds value to the conduct 
of CTC trials by within-trial and 
modelled economic evaluation, and 
also pursues independent research.
Our increasing income from 
public grants, which owes to our 
strong research record, indicates 
our competitiveness, with our 
collaborators, in a time of very tight 
funding. Together, we published 
170 journal articles and presented 
100 research studies at national 
and international conferences 
during 2015.
Success in any endeavour depends on 
diverse skills and expertise.  
We appreciate the joint efforts 
of many people. Collaborating 
investigator groups and other 
research organisations have come 
together to complete projects that 
will ultimately benefit many people 
worldwide. The CTC itself now 
numbers almost 200 people, most 
actively involved in research. The 
directors acknowledge the quality  
and energy of all their undertakings.
In this report we highlight some 
examples in which our staff and our 
collaborators have contributed to the 
future of medical research and patient 
care in 2015.
CTC executive:  
John Simes, director;  
Anthony Keech, deputy director; 
Wendy Hague, clinical trials 
program director; and  
Vera Terry, business director
Directors' report
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ActA international 
clinical trials 
symposium 2015
The Australian Clinical Trials 
Alliance staged the highly 
successful International Clinical 
Trials Symposium in October 2015, 
with the theme ‘Better Evidence 
Better Health’. It was a platform 
to discuss global advances toward 
self-improving health care systems, 
including embedding clinical trials 
in clinical care, challenges in trial 
design and conduct, maximising the 
value of clinical registries improving 
public awareness and consumer 
involvement in clinical research, and 
other issues of the moment.
The symposium attracted over 
500 people from all over Australia 
and elsewhere, including a faculty 
of 45 international and national 
speakers. It was a forum for everyone 
involved in funding, developing 
and undertaking clinical research. 
Attendees were clinicians, policy-
makers, triallists and researchers, 
clinical trial coordinators and nurses, 
biostatisticians, allied healthcare 
professionals, public health 
specialists, health economists, 
regulators and industry.
The symposium was a step taken in 
furthering ACTA’s aims to promote 
effective and cost-effective health 
care in Australia. 
The CTC, with its past experience of 
three previous such symposia, had 
a key role in organising the 2015 
symposium and contributed to its 
undoubted success.
Pictured at the rostrum,  
ACTA symposium chair and  
convener, Anthony Keech
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oncology progrAm
CTC collaborates with national and international investigator groups to develop 
and conduct trials and associated research in several areas of oncology— in 
gastrointestinal, gynaecological, urogenital, lung and brain cancer. The team 
of over 40 coordinate the trials from start-up to close-out, and are focused 
on development of new trials and other research initiatives, supported by 
infrastructure grants from the state and federal government.
The collaborative relationships with five of the national cancer cooperative 
groups (AGITG, ANZGOG, ANZUP, ALTG and COGNO) set the group apart 
from other research teams. Together, these collaborations are able to secure 
competitive funding to carry out investigator-initiated trials to improve the 
outcomes of cancer patients. As part of continuing efforts to better support 
colleagues at hospital sites, the group has established dedicated interactive trial 
pages on the CTC website for access by staff at hospital sites.
Strategic planning with cooperative group colleagues and through 
international links with similar research groups allows the CTC’s modus 
operandi to move forward in step with a changing clinical trials climate.  
The solid team and practices ensure that the group is well equipped to move 
with the developing landscape of trends to wider collaboration,  
more personalised medicine and targeted treatments.
CTC oncology executive. 
Left: Wendy Hague, clinical  
trials program director with  
Burcu Vachan, oncology program 
manager. Right: Cancer trials  
co-director, Martin Stockler  
with Mustafa Khasraw,  
clinical lead for brain cancer  
trials and Sonia Yip, oncology 
translational senior research fellow  
(not present: John Simes, Val Gebski  
and Katrin Sjoquist) 
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Altg
the ctc’s lung cancer trials 
are collaborations with the 
Australasian lung cancer 
trials group. the group aims 
to reduce the incidence, 
morbidity and mortality of 
lung and other thoracic 
cancers and improve the 
quality of life of patients, 
carers and families in 
Australia and new Zealand.
the Altg has been actively 
involved in developing 
high-quality trial concepts 
and supports the active 
engagement of its 
421 members—clinicians, 
researchers, allied health 
professionals and 
consumers—in all aspects  
of the development and 
conduct of its trials.
A novel idea to improve the effect of lung 
cancer chemotherapy
The NITRO trial was part of the search for better treatments for patients 
with lung cancer.28
The aim of NITRO was to test whether giving nitroglycerin via a skin 
patch would improve the effectiveness of chemotherapy. The patch had 
been beneficial for patients in a small trial in Japan. Also, there were 
good scientific reasons why nitroglycerin might improve the effect of 
chemotherapy, including possible enhancement of drug delivery, sensitising 
tumour cells to chemotherapy and reducing resistance to chemotherapy.
Half the patients were randomly allocated to having a nitroglycerin patch 
applied for five days around each chemotherapy infusion. The other half 
had chemotherapy but no patch. Most patients had carboplatin with 
gemcitabine as their chemotherapy treatment. 
Although the trial was to have 500 patients, a planned interim analysis 
at only 372 participants recruited had definitive results. Nitroglycerin had 
no effect on progression-free survival, nor on the response of the tumour. 
Because nitroglycerin did slightly increase the frequency and severity of 
adverse events, the investigators recommended that further research on its 
use not be pursued.
Most of the participants were men, and about two-thirds had been 
smokers within the past 15 years.
HiGHLiGHT: LunG CAnCeR
Sarah Chinchen, CTC-ALTG trials  
manager, who worked on the  
niTRO trial
Oncology staff, emily Tu, Claudia Bishop, Di Winter, Annie Yeung,  
nick Muljadi, Lesley Brassel and Anna Walsh
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everolimus for renal cell cancer in the eVersUn trial
The activity, feasibility and safety of a new drug regimen is customarily 
tested in a small group of patients in a phase 2 trial. Its results determine 
whether the regimen will go on to full evaluation in a randomised phase 3 
trial.
Several drugs are available for treating advanced renal cell carcinoma, 
the most common type of kidney cancer. EVERSUN was a phase 2 trial 
testing a regimen of alternating two of these: sunitinib and a more recent 
drug, everolimus. The rationale for the treatment was that switching two 
drugs with different mechanisms of action would prevent or delay drug 
resistance.29
Fifty-five patients participated. After 6 months, 29 were free of progression 
of their disease. The investigators had set the level for success of the 
regimen at 84% of patients without disease progression at 6 months, 
so they concluded that the results of the trial did not support further 
investigation of this novel regimen. However, the alternating treatment was 
safe and well tolerated.
The evidence from the trial suggested that clinicians should maximise 
the value from the individual drugs, as there was no evidence of benefit 
(or harm) from alternating them. 
As part of the trial, potential tumour biomarkers in blood were also tested 
to see if any specific tumour characteristics were related to success or failure 
of the regimen, but the chosen biomarkers did not correlate with individual 
outcomes. 
AnZUp 
the Australian and new Zealand 
Urogenital and prostate cancer 
trials group collaborates with 
ctc in clinical trial research to 
improve treatment of bladder, 
kidney, testicular and prostate 
cancers.
AnZUp brings together the 
professional disciplines and 
groups involved in researching 
and treating prostate and other 
urogenital cancers. 
AnZUp also works closely with its 
consumer advisory panel to 
achieve better understanding of 
consumer and community 
perspective on issues related to 
their clinical trials and to ensure 
that results are communicated 
back to patients and the 
community.
Salma Fahridin, in CTC’s  
oncology operations area
HiGHLiGHT: RenAL CAnCeR
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glioblastoma is an important target in the search 
for better cancer treatment
The CABARET trial of a potential treatment for glioblastoma 
is an example of a trial addressing an urgent clinical question. 
Glioblastoma is a serious brain malignancy provoking major 
research efforts. It is not common, but patients usually survive 
only a short time and there is no effective treatment if the disease 
recurs after chemotherapy. It is distressing for patients and their 
families and friends and has one of the highest average years of 
life lost for any cancer. It is treated with various chemotherapy 
agents, but there is no standard Australian treatment.
In CABARET, a large, multicentre phase 2 study, participants were 
randomised to a synthetic antibody, bevacizumab, along with 
chemotherapy, or to bevacizumab alone. In part 1 of CABARET, 
completed in 2015, bevacizumab alone did not benefit patients as 
much as expected, which may have been because some of them 
had had several recurrences.46 Also, combination therapy did not 
improve this result. Even so, some patients did respond to the 
treatment. In ongoing laboratory research, the relevant individual 
markers of benefit may be identified from tumour samples. 
When their disease recurred, patients graduated from Part 1 to 
Part 2 of the trial and were randomised again to continue or stop 
bevacizumab treatment. This second, exploratory, stage of the 
CABARET trial is continuing and when completed in 2016 will 
add value to the Part 1 results.
The trial has achieved international prominence and is likely to 
change international clinical practice.
cogno
collaborative research by 
ctc and the cooperative 
trials group for neuro-
oncology has the purpose 
of better outcomes for 
those with brain tumours, 
and others affected by 
these diseases, such as their 
families. cogno’s main 
aim is to conduct 
investigator-initiated and 
collaborative group trials 
addressing important 
clinical questions.
cogno now has members 
in new Zealand, singapore, 
canada, ireland, india, 
sweden and the UsA. the 
group also has consumer  
and industry associate 
members. cogno’s annual 
scientific meetings have 
been hugely successful in 
bringing together 
professionals from all  
over the world.
Mustafa Khasraw, oncologist, is the 
clinical lead for brain cancer trials at CTC
HiGHLiGHT: BRAin CAnCeR
Jenny Chow, executive officer of COGnO (right), with assistant Yi Feng
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AnZgog
the Australia new Zealand 
gynaecological oncology 
group conducts research into 
cancers of the ovaries, cervix, 
uterus, vulva and vagina at 
sites throughout Australia and 
new Zealand.
AnZgog collaborates with 
over 20 study groups in other 
countries through membership 
of the international 
gynecologic cancer intergroup. 
AnZgog has members in all 
medical and health specialties, 
as well as patients and other 
nonprofessional members, 
some of whom form an 
advisory panel for consumer 
outreach and trial 
development.
patient-reported outcomes validated
In ovarian cancer trials, the most common measure of the success of 
treatment is progression-free survival, that is, the time between starting 
treatment and when scans show that the disease becomes worse. But most 
women with ovarian cancer have advanced-stage disease and their priority 
is not progression-free survival but to maintain their quality of life and to 
reduce distressing symptoms.
The Symptom Benefit trial of palliative chemotherapy for ovarian cancer 
is an international collaborative study of ANZGOG-CTC investigators with 
other members of the Gynecological Cancer Intergroup. Traditionally, the 
outcome measured would be the size of the tumour measured by scanning 
or the level of cancer markers in the blood. Symptom Benefit is unusual in 
that its main focus is the subjective effect of treatment on the patients and 
their quality of life. 
Patient-reported outcomes can be more difficult to measure and analyse 
than objective outcomes. The investigators are acquiring insights into the 
symptom burden, patients’ and clinician’s expectations of treatment, and 
outcomes in a real world setting, with the aim of measuring the results of 
treatment in a way that is meaningful to patients.
From data from 852 trial patients, they developed a measure of ovarian 
symptoms and treatment concerns (MOST). This was recently validated in 
relation to trial outcomes and existing widely used ovarian cancer symptom 
scales.214 The MOST index has good validity and similar or better statistical 
efficiency than other scales.
Including patient-reported outcomes in trials also acknowledges the 
centrality of trial participants in research, and is one of the recent steps in 
the policies of CTC and its collaborators to ensure that patients are involved 
and informed at each stage of all trials.
Chemotherapy may improve a patient’s quality of life by reducing cancer 
symptoms and prolonging survival, or it may detract from quality of 
life because of 
the side-effects 
of drugs. Teasing 
out this balance 
through patient 
preference studies 
in various cancer 
types is a continuing 
research theme of  
the CTC.10,176,177
HiGHLiGHT: OVARiAn CAnCeR
JIM WEST/SCIENCE PHOTO LIBRARy
AnZ bctg
the Australian and new 
Zealand breast cancer trials 
group conducts a program of 
multicentre national and 
international clinical trials 
involving over 700 researchers. 
its trials cover all aspects of 
breast cancer, including new 
treatments, prevention, quality 
of life, and treatment cost-
effectiveness.
ctc is biostatistical centre for 
trials coordinated by the AnZ 
bctg, and has a formal 
relationship with the group 
spanning nearly 30 years.
10 
Lucy Davies, 
biostatistician 
for the 
A La CaRT  
trial
Personal story
reseArch fellow contribUtes  
to new internAtionAl triAls
I joined the CTC as a research fellow for the Australia New Zealand 
Gynaecological Oncology Group early in 2015, and I support the 
trial coordinators in their management of ongoing ANZGOG 
trials. It was quite a change compared with my job as a gynae-
oncologist in Oslo, Norway, but I immediately enjoyed the work 
in a multinational team. 
The collaboration with other international trial groups have 
provided some very interesting insight into the design and 
implementation of clinical trials. I had the opportunity to 
contribute to the protocol development of a surgical trial 
in endometrial cancer, and that work helped me a lot in my 
understanding of the processes but also the challenges and 
compromises involved in clinical trial development. 
We have just recently started a project to assess current 
perioperative care of ovarian cancer patients in Australia and New 
Zealand. I hope that this may turn into a continuing collaboration 
also with the NSGO (Nordic Society of Gynaecological Oncology), 
as I will return to Norway in 2016. It has been a privilege to work 
with this group of enthusiastic, skilled and supportive people.
Kristina Lindemann 
Research fellow, clinical oncology, AnZGOG trials
A la cart trial shows 
that evidence for routine 
laparoscopic surgery  
for rectal cancer is still  
to be established
Laparoscopic (or keyhole surgery) 
for abdominal operations has many 
obvious benefits and has become 
common with advances in surgical 
technology over the past 10 to 15 
years. Bowel tumours are often 
removed laparoscopically. For rectal 
cancer (the last 15 cm of the bowel), 
however, surgeons have been 
cautious because of uncertainty about 
removal of all parts of the tumour. 
Open surgery remains the standard 
treatment for many rectal cancers.
To this point, there has been little 
definitive evidence to guide surgeons 
about the safety and efficacy of 
laparoscopic versus open resection 
in rectal cancer. The multicentre 
Australasian Laparoscopic Cancer 
of the Rectum Trial (A La CaRT) is 
a collaboration of AGITG and CTC 
with colorectal surgeons in Australia 
and New Zealand. 472 participants 
were enrolled, 237 randomised to 
open surgery and 238 to laparoscopic 
surgery. Its aim is to find out whether 
laparoscopic surgery is as good as, or 
HiGHLiGHTS: GASTROinTeSTinAL CAnCeR
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promising treatment for  
oesophagogastric cancer
In Australia, there are around 3400 new cases a year of 
cancers at the junction between the oesophagus and the 
stomach. Around 2400 people a year die from these cancers. 
New treatment options are urgently needed, because when 
surgery and chemotherapy fail, no other proven effective 
treatments have been available.
The phase 2 INTEGRATE trial tested the potential 
of regorafenib as a treatment for these cancers.233,234 
Regorafenib is a relatively new biological treatment that 
had been in use for colon tumours and gastrointestinal 
stromal tumours.
An Australasia-led trial, INTEGRATE involved investigators and patients from Korea 
and Canada as well as Australia and New Zealand. The study recruited 152 patients 
across 54 centres in the four countries. The response of the tumours to the 
treatment was assessed relative to a prespecified benchmark, a median progression-
free survival of 8 weeks. The study also had a placebo arm as a calibration group to 
assess this reference. Patients receiving regorafenib had a significantly lower rate of 
disease progression at 8 weeks, 18%, compared with 46%in the placebo group. The 
Korean patients were more likely to benefit from treatment, a finding not explained 
by the trial, but it could be due to genetic or molecular differences affecting response 
to treatment or the way the drug is metabolised.
INTEGRATE was the first study to show activity of regorafenib in oesophagogastric 
cancer following failure of chemotherapy. A follow-up multinational phase 3 trial, 
INTEGRATE II, will start in 2016.
Agitg
the Australasian gastro-intestinal trials group has been conducting trials 
in gastrointestinal cancer with ctc for over 25 years. 
the group’s purpose is to achieve better health outcomes for patients 
with gastrointestinal cancers by conducting and promoting clinical and 
related biological research in Australasia and internationally.
the Agitg is strongly focused on encouraging members of the medical 
and scientific community to participate in Agitg-sponsored trials. 
members are actively engaged in identifying and developing novel clinical 
questions to answer in trials addressing common or rare gastrointestinal 
cancers. several of these trials have led to improvements in clinical 
management internationally.
eric Tsobanis,  
CTC manager  
of the inTeGRATe 
trials
no worse than, open surgery as an 
approach to rectal cancer.
In 2015, the investigators reported 
the first results of the trial, the 
comparison of laparascopic surgery 
and open surgery in terms of removal 
of all the tumour, in JAMA.132 The 
results were unexpected, confirming 
that experience and observation is 
no substitute for planned clinical 
trial evidence. The trial showed that 
non-inferiority was not ruled out. 
That is, open surgery might be better, 
but was not statistically different from 
laparoscopic surgery. The pathology 
results showed that the tumour was 
completely or almost completely 
removed in 97% of the laparoscopic 
surgery group and 99% of the open-
surgery group. There were low rates 
of complications and no differences 
between the two surgery groups in 
complications, pain or the time in 
hospital. On the basis of this evidence, 
surgeons will be cautious when 
considering a laparoscopic approach, 
which might be less successful for 
some patients, including those who 
are obese.
The trial was designed and conducted 
to ensure not only the best evidence 
but the best outcomes for patients. 
Surgeons could only take part after 
specific accreditation, which included 
video evidence of their expertise.
The trial participants will be followed 
up for 5 years for evaluation of other 
outcomes, such as disease-free 
survival, recurrence of the cancer 
and quality of life. Ultimately the 
case for recommending the routine 
use of laparoscopic surgery for these 
patients will be based on the long-
term outcomes of each procedure.
in 2015, Professor Philip Hogg became 
head and Professor of Translational 
Cancer Research for Sydney Catalyst, 
and also joined the CTC as Chair 
Translational Cancer Research
translational oncology research—
from bench to bedside
Translational research covers the full research pathway from laboratory 
science through clinical research and evidence-based clinical practice. From 
one point of view, it is a way to make the research process more efficient. It 
is also the foundation of personalised cancer treatment.
Typically, biological samples are collected from patients—for example 
blood or tumour tissue—then analysed for a range of biomarkers that are 
correlated with clinical outcomes to obtain indicators of risk. Biomarkers 
may predict the response of a patient to a particular treatment or forecast 
survival, an important part of personalising medicine. 
In over half of the trials that the CTC designs and coordinates, patients 
may choose to consent to their biological samples being used in research. 
As new technologies develop and scientific knowledge advances, these 
biospecimens might be analysed at a later time. For some trials, genetic 
or molecular testing of tissue is part of the process of screening potential 
patients for recruitment. The CTC and its collaborative groups now embed 
their trials in a translational pathway where possible, with the aim of 
future applications at the bedside. CTC’s oncology translational research 
collaborations across Australia include the Kolling Institute, Queensland 
Institute of Medical Research, the Centre for Translational Pathology, Peter 
MacCallum Cancer Centre, Monash University, NCIC Clinical Trials Group in 
Canada, and the MRC in the UK.
The CTC is a member of the virtual consortium, Sydney Catalyst, the 
Translational Cancer Research Centre of Central Sydney and Regional NSW. 
Sydney Catalyst is one of several translational cancer research centres 
funded by the Cancer Institute NSW. Sydney Catalyst brings together 
outstanding teams of researchers and clinicians from over 20 leading NSW 
institutions with the ability to undertake oncology translational research 
across the full continuum through basic biosciences, molecular biomarker 
discoveries, descriptive research, clinical trials, and implementation of best 
evidence-based care into practice. 
pancreas cancer treatment 
personalised in an 
ambitious novel trial
Advances in genetic testing 
have made it possible to choose 
suitable treatments on the basis 
of the characteristics of individual 
tumours. However, such personalised 
treatments have practical 
challenges, meaning that before 
they are validated in clinical trials, 
investigators have had to re-think the 
way trials are conducted.
The Individualized Molecular 
Pancreatic Cancer Therapy (IMPaCT) 
is a trial that used genome 
sequencing to choose the best 
individual treatment for each patient. 
IMPaCT screened pancreas tumours 
for three molecular targets: HER2 
amplification, which is treated with 
trastuzumab and gemcitabine; 
KRAS wild type, which is treated 
with erlotinib and gemcitabine; 
and mutations in DNA damage-
repair pathways (BRCA1, BRCA2, 
PALB2, ATM), which are treated with 
platinum-based chemotherapy.
The trial investigators assessed the 
conduct of the trial early in 2015 
when recruitment difficulties had 
become apparent. Of 93 patients 
who had the screening and 22 who 
were found to have one of the three 
molecular targets, only one went 
on to be randomised to specific 
treatment. This was because the 
disease could progress very quickly, 
HiGHLiGHTS: PAnCReAS AnD LunG CAnCeR
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collAborAtion AnD pArtnership in nAtionAl AnD internAtionAl triAls
meaning patients needed to start 
treatment immediately, while the 
process of obtaining and testing 
tumour specimens, with its many 
steps, was often not at the desired 
speed. Also some screened patients 
did not want to be randomised to 
treatment or they did not fit the other 
requirements to go on the trial.
When people with advanced cancer 
are being considered for targeted 
therapy, clinicians and scientists 
from various disciplines have to be 
able to work very quickly and in a 
coordinated way. Evaluating the 
treatment in a clinical trial is made 
even more complex and challenging 
by adding and standardising 
processes of obtaining consent, 
acquiring and analysing tumour 
samples, and discussing options of 
treatment. IMPaCT showed that we 
need rapid approaches when tumour 
samples need to be sequenced for 
clinical trials, and also to the way 
health care is delivered. 
The investigators published their 
experience, and adapted the trial 
to meet the challenges.18 The study 
used a central multidisciplinary 
team, working to produce faster and 
more focussed tissue analysis. Trial 
participants could receive standard 
treatment while they awaited 
molecular results. Nevertheless, the 
trial closed at the end of 2015.
The trial was a collaboration between 
Sydney Catalyst, the Australasian 
Gastro-Intestinal Trials Group and 
the CTC, in partnership with the 
Garvan Institute of Medical Research 
and the Australian Pancreatic Cancer 
Genome Initiative. 
A search for individual 
targeted treatment  
for lung cancer
Some cancer therapies work for some 
patients but not others. Many CTC 
research studies aim to identify the 
characteristics of patients or their 
tumours that will predict success of a 
particular treatment.
One of these studies has looked at 
treatment for non-small-cell lung 
cancer, the most common type of lung 
cancer. It resulted in new evidence 
that a drug that targets a genetic 
abnormality is better than chemotherapy, in terms of progression of 
cancer.83
The study, the largest so far in this area, was a collaborative project, led 
from the CTC and involving researchers from Australia, Taiwan, China, 
Japan, Spain and the USA. They analysed data from seven trials carried out 
in various countries evaluating treatment with an EGFR tyrosine kinase 
inhibitor. 
The study aimed to answer the important question: do patients with 
specific clinical characteristics or whose tumours have mutations benefit 
more from an EGFR tyrosine kinase inhibitor than chemotherapy? Most 
patients had one of the common EGFR mutations: exon 19 deletion or 
exon 21 L858R substitutions. About two-thirds had never smoked and 
about two-thirds were women.
The group of patients on the EGFR tyrosine kinase inhibitor, overall, 
benefited substantially from the drug, as compared with chemotherapy. 
The group whose tumours had a specific mutation (exon 19 deletions) did 
better on the drug than the group with the other mutation (exon 21 L858R 
substitution). Patients who had never smoked were more likely to benefit 
from the drug than smokers or ex-smokers, and women had slightly more 
benefit than men.
The study is a step in the endeavour to treat individual patients with the 
right drugs and to save others from suffering treatment regimens that 
may not help 
Chee Lee, oncologist and  
biostatistician, led the  
lung cancer meta-analysis
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cArDioVAscUlAr reseArch
extending trial results through international  
prospective meta-analysis
The CTC’s large-scale clinical trials in cardiovascular disorders are integrated 
in translational research. That is, the program combines trial results with 
other evidence to influence clinical care and policy decisions.
For example, the CTC’s large-scale cardiovascular trials, LIPID and FIELD, 
have both generated clinical evidence far beyond the outcomes of the trials 
themselves.
LIPID is part of the international Cholesterol Treatment Trialists’ 
Collaboration, whose secretariat is at CTC and Clinical Trial Service Unit in 
Oxford. CTC, a pioneer of prospective meta-analyses, was one of the lead 
instigators of the CTTC’s studies. The collaboration analyses data from, 
currently, 28 trials involving 175,000 patients, including the 9014 LIPID 
patients. One major analysis was published in 201524 and more are in 
progress.
The FIELD trial’s study drug, fenofibrate, was expected to benefit people 
with diabetes, because it reduces the levels of triglycerides in the blood. 
However, FIELD results revealed that it substantially reduced patients’ risks 
of amputation, kidney disease and eye disease, leading to ongoing further 
research in laboratory animals into the mechanisms of fenofibrate.269
cardiovascular disease trials  
provide data for markers of risk
Knowing an individual’s risk level for a heart attack or stroke can show 
when preventive treatment, such as statin drugs or lifestyle changes, will 
make a difference. The wealth of data from large cardiovascular trials allows 
researchers to continue to improve and refine models of risk. This is the aim 
of some of the cardiovascular research by the LIPID trial investigators (as 
our example shows),143 the FIELD trial investigators,108,109, 158, 159 and others.
CTC’s cardiovascular studies rely on a workforce with 
complementary skills in basic science, clinical medicine 
and biostatistics from several groups within the CTC.
New molecular and genetic markers in patients from 
CTC’s cardiovascular trials are being identified and 
validated, as a precursor to future work on finding 
new targets for prevention of heart and blood 
vessel disorders.
Diagnosis of cardiovascular 
risk in the lipiD study
People who have had a heart attack 
are at risk of another, as are those 
who have unstable angina. The 
LIPID trial showed many years ago 
how this risk could be reduced with 
statin therapy. The LIPID data has 
continued to provide new insights 
into cardiovascular risk. Most of the 
over 9000 patients provided samples 
of blood before and during the trial. 
Using these samples, the investigators 
recently analysed eight potential 
blood biomarkers of cardiovascular 
risk.143 These biomarkers were 
known to be associated with distinct 
physiological characteristics.
Of the markers in blood taken at the 
start of the trial, the best predictors 
were brain natriuretic peptide (BNP), 
a reflecting heart failure, and sensitive 
troponin 1, which is a marker of 
ischaemic heart damage. 
They were stronger predictors 
than the conventional risk factors, 
including age. The only stronger 
predictor was if their heart disease 
had led to a heart attack in the past.
Blood biomarkers may be changed 
over time by underlying physiological 
HiGHLiGHT: LiPiD
physiologicAl fActors 
AssociAteD with 
heArt DiseAse risk
•	 lipid levels
•	 inflammation
•	 blood flow and pressure
•	 hormones
•	 heart muscle damage
•	 kidney function
•	 blood clotting
preVenting cArDioVAscUlAr DiseAse
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conditions and the effects of medical 
treatment. In LIPID, half the patients 
were taking pravastatin to help 
prevent further cardiovascular events. 
The levels of potential blood 
biomarkers were measured after 
one year of treatment. Changes in 
the levels of some of the biomarkers 
over that year correlated with later 
cardiovascular events. Two, BNP 
and sensitive troponin 1, were 
familiar as predictors at baseline, and 
another was lipoprotein-associated 
phospholipase, which reflects 
inflammation.
As these biomarkers become more 
routinely measured, they are likely  
to be included with conventional 
risk factors in models for clinical 
decision making.
Personal story
phD reseArch with releVAnce  
to cArDiology prActice AnD gUiDelines
Since completing specialty training in cardiology I’ve been completing a PhD on 
statins and cardiovascular disease as well as a Master of Clinical Trials Research at 
the CTC, which have been highly complementary in improving my research skills.
Much of my work,, with statisticians at the CTC and the Clinical Trial Service Unit 
in Oxford, has involved analysis of data from the huge dataset of the Cholesterol 
Treatment Trialists’ Collaboration. In 2015, the CTC group analysed data from 
nearly 80,000 cardiovascular disease patients in 8 large trials. We found that 
statin therapy continued to have a benefit 5 years after the trials ended.197
We have also examined the accuracy of popular risk calculators used in practice by 
cardiologists: the Framingham, the QRisk2 and Pooled Cohort Equations.198 We 
compared these with the risk data of over 30,000 patients in 22 trials who did not have heart disease and were not 
taking statins. Our study found that risk is usually overestimated by these metrics.
In 2015 I was able to present some of this work at the American Heart Association meeting and Australian 
conferences.I’ve also been mentoring medical students and collaborating on various studies with other CTC 
researchers. Overall it has been a diverse and enriching experience.
Jordan Fulcher, PhD student 
in cardiovascular disease
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‘Are there any randomised trials my baby can join?’155
Trials of interventions that might lead to the best outcomes for extremely 
premature or other babies at high risk can be challenging. Trials must aim 
for the best long-term physical and psychological health of the child as well 
as successful discharge of the infant from intensive care. Neonatal clinicians 
and triallists make special efforts to acquire the trust of the parents at trial 
entry and maintain it during long follow-up periods. Neonatal trials often 
need to be large, because participation of hundreds or thousands of babies 
is needed for clear evidence of benefit of treatment. 
The CTC neonatal team work with clinicians through global partnerships 
in areas of need, such neonatal infection, oxygen therapy and simple cost-
effective measures to reduce neonatal problems.
The CTC’s neonatal group continues to grow, with more trials and more 
collaborations and more staff. The BOOSTII trials, which examined the 
optimum level of oxygen saturation for premature infants, were completed 
in 2015, for publication in 2016. Data from 1135 Australian and 973 British 
patients are being analysed together with results from four other trials in an 
international prospective meta-analysis, the NeoPROM collaboration. 
The Australian Placental Transfusion Study of deferred cord clamping for 
premature infants is now the largest trial of placental transfusion and is 
recruiting steadily. The LEAP1 and LIFT trials are using lactoferrin to treat, 
respectively, iron deficiency anaemia in pregnant women, and infection in 
preterm infants.
William Tarnow-Mordi, professor of neonatalogy
Lucille Sebastian, manager of 
PAeAn and APTS trials
A better fUtUre for newborns
The group is also establishing 
two new trials: TORPIDO2 
is investigating the 
developmental effects of 
targeted oxygenation in the 
respiratory care of premature 
infants; PAEAN is using 
erythropoieten plus cooling 
to treat infants who have 
suffered from low blood or 
oxygen supply to the brain at 
birth, and will assess them at 
two years of age.
Improvement of specific 
methods for and approaches 
to neonatal trials is a 
central concern of CTC 
investigators.138 
One of the aims of the 
neonatal group is to promote 
moves toward a health system 
in which every premature 
infant has the opportunity to 
participate in a clinical trial.155 
An important aspect of this is 
including parents and others 
with the experience of having 
a premature or fragile infant 
when neonatal trials are being 
designed and conducted. 
These valued parent 
contributors also have roles in 
recruitment of patients and in 
publication of the results.106
Personal story
mAnAging triAls to improVe sUrViVAl of newborns
I work with leading Australian and International neonatal researchers 
developing new studies and implementing funded studies. 
We have a number of large neonatal trials ongoing, and no two projects, 
and no two days in the office, are alike. The size and the motivation of the 
neonatal team is at the highest that has ever been at CTC as we coordinate 
and manage several studies for better outcomes for premature babies. 
Because of the size and duration of baby trials, seeing a project through 
from its conception to completion is rare for a project manager. For me it 
has been extremely rewarding to be part of the team to submit a paper of 
the results of one such trial in the New England Journal of Medicine under 
the leadership of our charismatic leader William Tarnow-Mordi, professor 
of neonatal medicine at the CTC. He is a champion of trials to improve the 
treatment and prospects of newborn babies. He says ‘Randomised trials are 
the best way to determine which treatments provide the best outcomes. 
More trials of other treatments for premature babies are urgently needed to 
improve their quality of survival. With innovative investment in clinical trial 
networks and point of care data capture, trials like these could finish much 
faster, at a fraction of the cost’. 
Alpana Ghadge, Project manager, neonatal trials
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DiAbetes reseArch CTC’s diabetes group undertakes research into type 1 and type 2 diabetes. The 
team consists of clinicians and laboratory scientists who work with colleagues in 
other countries, particularly India, the United States, Qatar, the United Kingdom, 
Israel and Ireland, and in remote parts of Australia. These varied projects are 
funded by government and non-profit agencies and charities that aim to reduce 
the burden of diabetes nationally and internationally. 
The team’s research focus includes:
•	 biomarkers related to diabetes outcomes in type 1 and type 2 diabetes
•	 prediction and prevention of diabetes and diabetes complications in children 
and adults 
•	 use of technology in type 1 diabetes care, including insulin pumps
•	 use of telehealth to improve outcomes for Indigenous Australians with 
diabetes in remote regions of Australia
•	 Clinical trials: T4DM (testosterone for men with pre-diabetes), REMOVAL 
(metformin for prevention of cardiovascular complications), FAME-1 
Eye (fenofibrate for prevention of retinopathy in type 1 diabetes), FIELD 
(biomarkers as indicators of diabetes complication risk) and closed loop 
insulin pumps in the home.  
The group also collaborates with Insulin For Life and the International Diabetes 
Federation Life for a Child in research that supports some of the world’s most 
vulnerable people with diabetes. The research includes simple health economics 
analyses showing the impossibly high costs of essential medicines for a poor 
child with type 1 diabetes in many disadvantaged countries and assessment of 
how families without refrigerators can keep insulin cool. 
Students are a valuable part of their research team, with all receiving 
scholarships, publishing in peer-reviewed journals, and most presenting their 
research at national and international conferences.
From back row left: Andrzej 
Januszewski, Ryan Farr, Daniel 
Calandro, Alicia Jenkins, Anandwardhan 
Hardikar, Sarang Satoor, Wilson Wong, 
Mugdha Joglekar, Sven-erik Bursell, and 
visiting researcher Dvaki Kher
DiAbetes AnD VAscUlAr DiseAse
HiGHLiGHT: DiABeTeS AnD iSLeT BiOLOGY
thin rats and fat rats:  
ancestral diets determine  
vulnerability to type 2 diabetes
The middle classes from developing countries are 
more susceptible than western Caucasians to obesity, 
type 2 diabetes and cardiovascular disease in today’s 
changing environment. This may be a result of the 
nutrition endured by their ancestors.
Unsurprisingly, increasing prosperity in developing 
countries has been accompanied by a sudden 
increase in caloric intake across the population, 
but their epigenetic make-up (whereby changing 
environmental factors alter how people’s genes are 
expressed) has not compensated for these dietary 
changes. This means their bodies are still designed to 
cope with undernourishment; so they store fat in a 
manner that makes them more prone to obesity and 
its resulting diseases than populations accustomed to 
several generations of a ‘normal’ diet.
The latest research from the Diabetes and Islet 
Biology group, published as a cover story in Cell 
Metabolism,57 demonstrates from an experimental 
model using rats that eating a ‘normal’ diet can 
make animals obese if their ancestors have been 
undernourished for several generations.
This scenario was created in a 12-year study of two 
groups of rats. The first group was undernourished for 
50 generations and then put on a normal diet for two 
generations. The second (control) group maintained 
a normal diet for 52 generations. At the end of the 
study, the descendants of the first group were exposed 
to a normal diet, but the epigenetic modifications of 
their undernourished forebears persisted. These rats 
were eight times more likely to develop diabetes and 
multiple metabolic defects than the control group. 
Lower vitamin B12 levels in the undernourished rats 
could also be an indicator of this trend. 
With increasing migration of populations from 
developing to affluent countries, there is a need to 
identify factors that minimise their risk of diabetes 
and obesity—one of Australia’s national health 
priorities. Laboratory studies like this one start the 
process by enlightening us on the circumstances of 
metabolic disorders.
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Personal story
lAb reseArch motiVAteD by cUriosity AboUt science
I have always loved to explore biology and discover new areas of science. 
I think this curiosity to understand, identify and investigate newer areas 
of research got me interested in pursuing science as a career. I work 
with Professor Alicia Jenkins and Associate Professor Anand Hardikar 
in the Jenkins-Hardikar lab as a JDRF international postdoctoral fellow, 
pursuing my interests in microRNAs and epigenetics. I was recently 
awarded the ADS Skip Martin Fellowship, followed by the JDRF (USA) 
advanced postdoctoral fellowship for work aimed at understanding the 
molecular mechanisms involved in immunomodulation and diabetes. 
I am involved in multiple projects that will identify molecular cues 
during pancreas development and diabetes, so as to apply this knowledge 
towards development of therapies aiming to retard the death of insulin-
producing cells and complications of diabetes.
These form foundation steps toward improving the treatment of diabetes.
Mugdha Joglekar, senior 
research fellow in diabetes
Personal story
islet biology AnD DiAbetes 
My major research interest is early prediction of diabetes and its 
complications. Research in our state-of-art, purpose-built laboratory is 
focused on understanding islet biology and development of insulin-producing 
cells. We work with cadaveric human pancreatic islets as well as biliary 
duct- and gallbladder-derived cells to gather information that would help us 
understand development of insulin-producing cells. 
Other projects in the lab are focused on understanding the epigenetic 
modifications in insulin-producing cells in a unique model of multigeneration 
undernutrition. These studies involve understanding the influence of 
diet, micronutrients, intrauterine programming and gut microbiota in 
development of central adiposity, insulin resistance and type 2 diabetes. 
As part of this research, we are interested in analysing baby poo to understand 
how gut microbiota are established in the immediate postnatal period. We 
aim to identify the mechanisms that link gut microbes to development of 
diabetes and metabolic disease.
Anandwardhan Hardikar,  
who leads the islet Biology 
and Diabetes research team
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systemAtic reViews AnD Assessment  
of tests AnD technology
The CTC’s systematic reviews and health technology assessment group 
integrates trial results and other findings of health research to obtain the best 
unbiased evidence to support effective and efficient health policy and practice.
A systematic review of high-quality trial data, with reanalysis of the data at 
an individual-patient level is the optimal way to arrive at valid evidence to 
underpin clinical and policy decision making. Such a meta-analysis enlarges the 
participant pool from the limitations of a single trial and therefore can increase 
the statistical power of the results.
Where a local population is too small to support a large trial, a meta-analysis 
of several far-flung trials can be a substitute, especially where the investigators 
cooperate to plan their coordinated trials in advance in a prospective meta-
analysis. Examples can be found in neonatology, where extremely high numbers 
of participants are required to reach the statistical power to prove a result, 
and cardiovascular disease, where common serious disease means there are 
high numbers of patients and large trials. CTC has provided leadership in the 
rationale and implementation of many of these.
Systematic reviews of available evidence are recommended as the starting point 
for any new research study, even before funding is applied for. A review will 
show whether the new trial is actually needed and where the gaps in evidence 
are. CTC undertakes such reviews as part of the process of beginning a new 
study.15,101, 184, 185 Such reviews also inform the methods of CTC trials17 and extend 
and generalise results obtained from CTC trials.219
CTC contributes internationally to advances in the methodology of systematic 
reviews, through leadership in the Cochrane Prospective Meta-Analysis 
Methods Group. In 2015 the group published a review of on how meta-analyses 
influence the progress of subsequent medical research.142 CTC is also the 
editorial base of Cochrane Breast Cancer, which oversees Cochrane’s systematic 
reviews of evidence in all aspects of breast cancer.They recently published two 
new reviews on lymphoedema and also produced a final update of their review 
of the value of taxane chemotherapy for metastatic breast cancer.54
CTC’s Lisa Askie, director of the 
CTC’s systematic review group, 
is a convener of the Cochrane 
Prospective Meta-Analysis 
Methods Group
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HiGHLiGHTS: SYSTeMATiC ReVieWS
how do doctors know that 
using a new clinical test will 
be worthwhile?
Evaluation of diagnostic tests has 
been an area of interest for CTC 
researchers for many years. It is a 
complex process involving many 
steps. Evaluation takes in methods 
for arriving at the best evidence of the 
benefits of treatment, such as clinical 
trial evidence.
A new test may detect a disorder 
accurately, but that is only the start. If 
detection of a disorder does not lead 
to more and better treatment, the 
test may be useless in practical terms. 
If it detects a harmless disorder, the 
test may lead to overtreatment. 
Therefore, evaluating a new test must 
take account of the consequences 
of diagnosis and the effects of 
the subsequent treatment for a 
patient. The final outcome in the 
treatment pathway is what matters 
most. Ideally, the benefits of a new 
diagnostic test are evaluated by a 
randomised trial, but CTC researchers 
are looking for simpler and faster 
ways of determining whether a new 
test should be adopted in place of an 
old one.
The Test Evaluation Working Group 
of the European Federation of 
Clinical Chemistry and Laboratory 
Medicine, with Sally Lord, have 
applied these principles to examining 
the relative advantages of different 
ways of specifying the performance 
of laboratory tests.64 These tests can 
be used for many purposes, such as 
screening, diagnosis, prognosis, risk 
assessment, selection of treatment, 
and monitoring the effects of 
Personal story
stUDies of clinicAl tests AnD DiseAse risks 
inVolVe DiVerse skills AnD A mUltiDisciplinAry 
teAmwork
My research area is studies of medical tests, biomarkers and clinical 
risk prediction models. My goal is to help develop and evaluate the 
use of these ‘tools’ to improve the understanding and classification 
of disease to guide treatment decisions. The skills and expertise 
needed for these traverse epidemiology, clinical medicine and 
research methodology.
I work with clinicians, biostatisticians, laboratory scientists and 
health economists. My role is to contribute to study design, 
analysis, interpretation and reports. Recent studies range from 
biomarker discovery83 to a pragmatic randomised controlled trial of 
implementing a new model of risk.81 We used the model to predict 
how likely it would be that a patient presenting to the emergency 
department with chest pain and a non-diagnostic ECG was having a 
serious coronary event.
Other studies take advantage of existing treatment trial data to 
evaluate biomarkers and develop models to improve treatment 
selection.105 I also collaborate with international groups to improve 
the methods for evaluating diagnostic and other clinical tests.
I feel very fortunate to be working with such a multidisciplinary 
group at CTC. I enjoy the collegial spirit and the lively open 
discussion of research questions and problems.
Sally Lord, senior research fellow, is an epidemiologist and clinical 
researcher, whose work is at the forefront of new ideas in decision analyses 
and evaluation of health technologies and tests
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treatment. A laboratory test can be 
evaluated on the basis of randomised 
evidence of its direct outcomes for 
the patient (using a controlled clinical 
trial that measures the endpoint). 
Alternatively, it may be evaluated 
on linked evidence from simulation 
models of real-life clinical decision 
making, which use data from a variety 
of existing studies. The latter is faster 
but the model may be diluted by the 
diversity of clinical practice, leading to 
evidence that may be less strong than 
that generated by a clinical trial.
An analysis of Australian 
clinical trial activity in 
relation to national health 
priorities
Clinical trials provide high-quality 
evidence of the effectiveness, or 
not, of treatments and other health 
interventions in health care. But the 
results of trials are only important if 
there is a need for treatment in that 
area.
In the first overview of clinical trial 
activity in Australia, a recent CTC 
study assessed whether clinical 
research being done reflects national 
priorities, defined by the burden of 
disease (box).80
The researchers had access to 
detailed data from the Australian 
New Zealand Clinical Trials Registry, 
a national resource sited at the CTC. 
They measured the number of trials 
(as a proxy for the number of current 
research questions) and the planned 
recruitment to those trials (to show 
the number of patients actively 
participating in research) in the nine 
national health priority areas.
From an analysis of 5143 registered 
trials recruiting participants in 
Australia, the main finding was that 
obesity, dementia and asthma are 
under-researched. These areas have 
few trials with few participants in 
relation to their disease burden. 
Cancer and cardiovascular disease, 
on the other hand, have high trial 
activity, with mental disorders not far 
behind.
The registry collects data on the 
design of trials, health conditions 
treated, treatments or interventions, 
planned recruitment, outcomes of 
treatment, funding and sponsorship. 
It is one of several national registries 
recognised by the World Health 
Organisation. To date, 11,460 trials 
have been registered. The team at 
the CTC continues to improve the 
functioning and utility of the registry 
and monitor the characteristics of 
Australasian trials research. They 
keep up to date with international 
guidelines for accountability and 
transparency in clinical research.
One of the original purposes of the 
registry was to allow investigators 
from anywhere in the world to get 
CTC’s AnZCTR project officers  
Ava Tan-Koay, Slavica Berber,  
Kylie Hunter and Ailsa Langford
information on current research 
endeavours before they embarked on 
a trial. Registries like the Australian 
one are important for preventing 
duplication of research effort. Now, 
the findings of this new study are 
showing researchers and policy 
makers where to direct their attention 
to reduce the burden of disease in 
Australia.
nAtionAl heAlth 
priority AreAs
•	 cancer control
•	 cardiovascular health
•	 mental health
•	 injury prevention and 
control
•	 Diabetes mellitus
•	 obesity
•	 Arthritis and 
musculoskeletal 
conditions
•	 Dementia
•	 Asthma
heAlth economics
Proven new health-care treatments 
must be shown to be value for money 
before they can be put into practice, 
whether they are publicly or privately 
funded. Affordability must be justified 
in a national climate of increasing 
competition for funding. Economic 
evaluations have long been integral 
to CTC’s trials and systematic reviews 
of evidence. This is the responsibility 
of the health economics group.
The group also pursues collaborations 
with other trial groups, such as in 
melanoma and kidney disease.
Economic evaluation is prioritised 
and incorporated into trials when: 
1. Evidence of cost-effectiveness is 
needed or is likely to help decision 
making (that is, whether the 
intervention is cost-effective or  
not cost-effective); 
2. When the intervention is known 
to be expensive; or 
3.  When the intervention has a 
substantial impact on quality 
of life.
Typically, this is conducted alongside 
phase 3 clinical trials, but economic 
evaluations often require additional 
modelling to make use of all the 
available evidence.
Economic evaluation also includes 
studies of preference elicitation, 
which answer questions about 
patient, clinician or community 
preferences for particular aspects of 
screening or treatment using discrete 
choice experiment methods. These 
studies can inform the design of new 
interventions used in trials and advise 
on incentives or reimbursement in 
health policy.
The health economics group 
is involved in policy-relevant 
implementation science,  
in particular budget impact  
analyses, to determine the financial 
impact of ‘rolling out’ new cancer 
treatments and programs nationwide, 
for example, the impact of specialised 
surveillance clinics for people at high 
risk of melanoma skin cancer.95
Finally, the health economics 
group leads research in the area 
of health equity, with a focus on 
the financial impact of cancer and 
chronic kidney disease on individuals 
and households.228–230 Several 
projects have been undertaken 
with the Cochrane Equity Methods 
group to incorporate health equity 
considerations into systematic 
reviews and guidelines.
Kidney dialysis
ALAMAy
Cancer radiotherapy
DR. P. MARAZZI/SCIENCE PHOTO LIBRARy
 CLINICAL TRIALS CENTRE: 2015 RESEARCH REPORT 25
best eViDence, best policy, best prActice
‘the shArp study highlights 
the large proportion of 
patients with ckD who are in 
financial hardship, which is 
not restricted to people 
living in low- or middle-
income countries, but 
includes those living in 
relative poverty in high 
income countries such as 
Australia. successful kidney 
transplantation may benefit 
not only the individual in 
terms of their health and 
quality of life, but also the 
economic stability of their 
household.’
—Rachael Morton
Does health affect wealth?
Advanced stages of chronic kidney disease may cause considerable financial 
strain for patients and their families.
To find out whether the severity of chronic kidney disease and side-effects 
associated with the disease and its treatment were associated with a fall into 
poverty, Rachael Morton and her colleagues studied people participating in the 
international Study of Heart and Renal Protection (SHARP), who were followed 
up for a median of 5 years.229
Of the 2914 people with moderate to severe kidney disease, 933 were in 
poverty at the time of screening and a further 436 had moved into poverty by 
the end of the study. The severity of the disease was a significant predictor of a 
fall into poverty, as were low education and low income. People who received 
kidney transplants were much less likely to fall into poverty. 
The authors concluded that kidney transplantation may have a role in reducing 
the risks of household poverty due to chronic kidney disease.
HiGHLiGHT: SHARP STuDY
Associate Professor Rachael Morton, director of health economics  
and SHARP study investigator
Does education level make 
a difference to health?
In another study, with data from 
over 9000 people with chronic 
kidney disease, the SHARP 
investigators examined the 
relationship between education  
level and progression of kidney 
disease, cardiovascular events  
and death.98 Cardiovascular risk  
and mortality were both associated 
with low education, but most of  
this risk was attributed to lifestyle 
factors and poor health literacy. 
Surprisingly, education level 
generally was not related to 
progression of kidney disease.
26 
biostAtisticiAns Are centrAl to  
innoVAtion in clinicAl triAls
The CTC’s biostatistics group are innovators and practitioners in all areas 
of clinical trial methodology. They lead the design and analysis of trials of 
the CTC and its collaborative groups. They take part in the trials of national 
and international groups. CTC has a long-standing role as a biostatistical 
centre for the Australian and New Zealand Breast Cancer Trials Group.167, 270
All the biostatisticians also collaborate in research in hospitals and 
universities in Sydney, visiting these sites and helping clinicians and 
others conduct their research to rigorous standards. They therefore find 
themselves involved in many varied areas of medicine, such as radiation 
oncology,37, 38, 102, 113, 140 emergency medicine,67 childbirth,41, 42, 75, 145 
immunology,11,65, 181 urology,55,103 neurology,115 ophthalmology,118,162 and 
medical education.126,148
Back at the CTC, they also undertake studies in statistical methodology to 
improve approaches to clinical trials. An example is the recent exploration 
of heterogeneity in global clinical trials, which showed that the apparently 
large variation in a country-specific treatment effect could be due to 
chance.124
Vitamin b3 derivative 
cuts risk of new 
skin cancers: ontrAc 
(oral nicotinamide to 
reduce Actinic cancer)
Positive results from ONTRAC, an 
important study on prevention of 
skin cancer by University of Sydney 
researchers, were published in the 
New England Journal of Medicine 
in October.19 The investigators 
found that a year of treatment with 
nicotinamide, a form of vitamin 
B3, significantly lowered the risk 
of common, non-melanoma skin 
cancer in people who were at high 
risk because they had already had 
such skin cancers.
HiGHLiGHT: OnTRAC
Andrew Martin, senior biostatistician 
and OnTRAC investigator
Professor Val Gebski and Valérie Garès,  
research fellow in biostatistics
Rachel O’Connell, senior biostatistician
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high-qUAlity clinicAl reseArch in biostAtistics
CTC’s senior biostatistician, Andrew 
Martin, is an ONTRAC chief 
investigator, and presented the results 
at the meeting of the American 
Society of Clinical Oncology.225
In Australia, non-melanoma skin 
cancer affects more than half of 
the population. It is four times 
as common as all other cancers 
combined, and costs the nation more 
than $500 million annually. 
The most common types are 
squamous cell carcinoma and basal 
cell carcinoma. Squamous cell 
carcinomas can spread to lymph 
nodes and internal organs. Basal 
cell carcinomas rarely spread but 
can cause huge cosmetic problems, 
as they often occur on the face. 
Nicotinamide was equally effective in 
preventing both types. 
The study was not designed to test 
whether nicotinamide would benefit 
people in the general population who 
have not had skin cancer, or whether 
it would affect melanoma.
This study built on a decade of 
evidence from preclinical and early 
clinical studies, which suggests 
nicotinamide enhances the repair 
of DNA in skin cells damaged by 
sunlight. Nicotinamide also appears 
to protect the skin’s immune 
system from ultraviolet radiation by 
providing skin cells an extra energy 
boost when they are in repair mode 
after sun exposure.
The ONTRAC study was funded by 
the National Health and Medical 
Research Council and conducted at 
Royal Prince Alfred and Westmead 
Hospitals in Sydney.
Personal story
VAriety in internAtionAl  
collAborAtion for ctc biostAtisticiAn
Working in collaboration with other international organisations 
has provided a useful and challenging insight into how other 
institutions are run. The biostatistics team at the CTC are currently 
in collaboration with AstraZeneca, based in the UK, and Gineco, 
based in France, on the SOLO2 trial, which is a multicentre phase 3 
study of olaparib in patients with BRCA-mutated advanced ovarian 
cancer.
My role in the project is, as part of a team, to replicate primary trial 
results calculated by the AstraZeneca team. It has been very useful 
to work on new techniques that are incredibly useful in helping to 
develop my own statistical knowledge further.
So far, the project has been an experience that I am very much 
enjoying, despite a few challenges along the way. It has also 
been a privilege to represent the CTC at an international level 
and something I am very much looking forward to continuing 
in the future.
emma Gibbs, biostatistican
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Personal story
ctc biostAtisticiAns benefit  
from being pArt of A VitAl groUp
Every CTC trial is unique, and our trials often 
present new methodological problems that 
challenge us to find a solution that ensures trial 
results and conclusions are valid for general 
practice.
One problem that I have worked on involves a 
cardiovascular study in which participants could 
experience multiple events of different types (such 
as angina and a stroke) over time. We aimed to 
establish how these events are interconnected, 
and how we can use this information to estimate 
the risk of a future event, and see if we are able 
to summarise the complex effects of a trial 
treatment in a simple way.35
I’m fortunate to be part of a strong team of 
biostatisticians at the CTC, who have a wide 
range of experience that we can draw upon. We 
have a regular ‘discussion forum’, when members 
of the team present their recent problems to 
the group. We bounce ideas off each other and 
suggest potential angles of attack in searching for 
a solution. These have proven to be invaluable 
learning experiences for me, and will no doubt 
continue to improve the way that clinical trials are 
conducted at the CTC.
Mark 
Donoghoe, 
biostatistician
trial of on-the-spot emergency 
medical treatment for severe head 
injuries
If a person is unconscious after being hit in a motor 
vehicle accident or falling from a building, does it 
help to send a specialist physician as well as the 
paramedic team? The Head Injury Retrieval Trial 
(HIRT) was an attempt to obtain definitive evidence 
on whether physician treatment in addition to 
standard paramedic treatment results in better 
outcomes for people with severe blunt traumatic 
brain injury.51
Physician-staffed prehospital services can provide 
a wider range of stabilising and rescue procedures 
than paramedics. Observational studies and reviews 
had suggested that the long-term outcomes for 
patients may be better, although the cost per life 
year saved, especially if the physician is sent by 
helicopter, is very high.
The HIRT trial, by Careflight, Westmead Hospital  
and CTC, was conducted in the Sydney area. 
It was complex, incorporating protocols of the 
Royal Australasian College of Surgeons and the 
NSW Ambulance Service, resulting in practical 
challenges that may need to be addressed in future 
studies. Helicopter flights were limited by the hours 
of daylight, reducing recruitment to the trial in 
winter. Recruitment could not be expanded to new 
jurisdictions, but had to be restricted to areas where 
ambulance protocols and policies allowed random 
allocation of patients. The trial design had to allow 
for unexpected sudden changes to the planned 
treatment or allocation of patients if the situation 
required it. Of the patients randomised to the trial, 
many were then excluded because their injuries 
did not fit the eligibility criteria, or they were not 
transported to a trauma centre, or they died before 
the emergency team arrived. The comparison of 
the randomised groups did not show a difference, 
but this could well have been because so many 
patients did not receive their allocated treatment. 
In an analysis of the groups as actually treated, the 
death rate was significantly lower in the medically 
treated group.
HiGHLiGHT: HiRT
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eDUcAtion
eDUcAtion
masters degree in 
clinical trials research 
The University of Sydney’s Clinical 
Trials Research postgraduate course 
leads to formal qualifications in the 
design, conduct and interpretation of 
clinical trials. 
It was developed by the CTC in 
response to a need for understanding 
of clinical trials and their regulations 
by health care professionals, who 
increasingly find that research is 
a customary part of a clinical role. 
Students complete the course with 
a solid understanding of research 
methodologies, clinical trials literature 
and the clinical trials process, 
including design, regulations, and 
statistical and ethical considerations. 
The program is delivered 100% 
online, including lectures, discussion 
forums and supplementary notes. 
The course is taught online by 
clinicians and researchers who have 
designed, conducted and published 
more than 150 clinical trials over the 
past 28 years, as well as teaching 
short courses, masterclasses and 
seminars over that time. It is 
coordinated by Adrienne Kirby,  
Val Gebski and Anthony Keech. 
biostatistics collaboration of Australia
The Biostatistics Collaboration of Australia (BCA) is a consortium of biostatistical 
experts from around Australia with representatives from universities, government 
and the pharmaceutical industry who have combined to offer a national (and 
international) program of postgraduate courses via an alliance of universities. 
The BCA program is delivered entirely by distance by consortium universities and 
administered from the CTC. Over 300 students are enrolled, 164 of them new in 
2015, and on graduation will contribute to solving the shortage of well qualified 
biostatisticians in Australia and elsewhere.
CTC honorary associate researcher in cardiovascular disease, Boris Waldman, with his 
supervisors, Val Gebski, Tony Keech and Alicia Jenkins, at his graduation.  
Boris received the university of Sydney Medal and other prizes in the university’s 
graduate medical program
Adrienne Kirby (right), senior CTC statistician, is co-coordinator of the postgraduate 
clinical trials course, here with Rebecca Asher, biostatistician
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cUrrent ctc triAls
TRiAL PARTiCiPAnTS TARGeT ACCRuAL
neOnATAL DiSORDeRS
Trials in start-up
torpiDo2: Targeted oxygenation in the respiratory care of  
premature infants at delivery: effects on developmental outcome
Neonates born before 29 weeks’ gestation 1200 —
CTC-led study
pAeAn: Preventing adverse outcomes of neonatal  
hypoxic ischaemic encephalopathy
Newborn infants with signs of brain damage 300 —
CTC -led study
Current trials
Apts: Australian placental transfusion study Neonates born before 30 weeks’ gestation 1600 1288
CTC-led study
leAp: Lactoferrin evaluation in anaemia in pregnancy Pregnant women with anaemia 900 143
CTC-led study
lift: Lactoferrin infant feeding trial Infants born weighing under 1500 g 1100 143
CTC-led study
Trials in follow-up
Apts echo: Australian placental transfusion study (Echo substudy) Neonates born before 30 weeks’ gestation  242 266
CTC-led study
CARDiOVASCuLAR DiSORDeRS
Trials in start-up
cArsk: Canadian-Australian trial screening  
for coronary artery disease
Kidney transplant candidates 3306 –
RPA, Westmead, St Paul’s, Auckland City hospitals,  
University of Sydney, CTC study
Trials in follow-up
fielD: Fenofibrate intervention and event lowering in diabetes Patients with type 2 diabetes 8000 9795
CTC-led study
lipiD: Long-term intervention with pravastatin in ischaemic disease Patients with a history of coronary heart disease 9000 9014
CTC-led study
DiABeTeS
Trials in start-up
e-preDice: Early prevention of diabetes complications in people 
with hyperglycaemia in Europe and Australia
Adults with hyperglycaemia 100 (Australia); 
3000 (int.)
—
International study, BIONE and CTC
fAme1-eye: Fenofibrate and microvascular events in type 1 diabetes 
CTC-led study
Adults with type 1 diabetes and nonproliferative 
retinopathy
450 —
Current trials
Performance of closed-loop artificial pancreas at home  
compared with best available technology
People with type 1 diabetes 24 —
St Vincent’s Hospital, Melbourne, JDRF, Medtronic, CTC study
remoVAl: Effects of metformin added to insulin on  
atheroma progression 
Adults with type 1 diabetes at risk of 
cardiovascular disease
105 (ANZ);  
450 (int.)
106(ANZ);  
450 (int.)
University of Glasgow and NHS-led, and CTC study
t4Dm: efficacy of adding testosterone to a lifestyle program  
to prevent progression to type 2 diabetes
Men with prediabetes and low testosterone 1500 591
University of Adelaide and CTC study
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Trials in follow-up
teAmsnet: using internet and mobile technologies for  
coordinated diabetes and heart 
Indigenous people from remote and rural 
Australian communities
600 600
University of Melbourne, Fred Hollows Foundation, AMSANT, CERA, CTC study
OnCOLOGY
Current trial
itool: Evaluating a web-based tool for estimating and  
explaining prognosis 
CTC study
Patients with incurable cancer who attend clinics 
of participating oncologists and who want 
information about life expectancy
70 patients;  
70 oncologists
219 patients;  
28 oncologists
BReAST CAnCeR (COLLABORATinG WiTH RACS)
Current trials
snAc 2: Sentinel node biopsy versus axillary clearance 
RACS and CTC study
Women with operable breast cancer, stratified by 
factors including age and tumour size
 1012 326
Trials in follow-up
snAc 1: Sentinel node biopsy versus axillary clearance  
RACS and CTC study
Women with a single operable breast tumour 
<3 cm, stratified by factors including age and 
tumour size
1000 1088
GASTROinTeSTinAL CAnCeR (COLLABORATinG WiTH AGiTG)
Trials in start-up
ActiccA-1: Phase III trial of adjuvant gemcitabine and cisplatin 
chemotherapy compared with observation
Patients with biliary tract cancer after resection 440 (int.) —
AIO (Germany)-led, AGITG, and CTC study
control nets: phase II open-label trial of lutetium-177 octreotate 
added to capecitabine and temozolomide for neuroendocrine 
tumours
Patients with pancreatic or midgut 
neuroendocine tumours
165 —
AGITG and CTC study
nAbnec: Phase II study of nab-paclitaxel and carboplatin  
as first-line treatment 
Patients with advanced gastrointestinal 
neuroendocrine carcinoma
80 —
AGITG and CTC
Current trials
Alt gist: Imatinib alternating with regorafenib  
compared to imatinib alone for GIST 
Adults with previously untreated metastatic 
gastrointestinal stromal tumours
240 10 (ANZ);  
14 (int.)
AGITG, CTC, SSG, EORTC study
Ascolt: Aspirin for Dukes C and high-risk Dukes B colorectal cancers 
National Cancer Institute (Singapore)-led, AGITG and CTC study
Patients with colorectal cancer who have 
completed surgery and other treatment
200 (ANZ);  
2660 (int.)
121 (ANZ);  
790 (int.)
Doctor: Phase II trial of preoperative cisplatin, 5-fluorouracil and 
docetaxel with or without radiotherapy for oesophageal cancer
Patients with resectable adenocarcinoma of the 
oesophagus not responsive to chemotherapy
150 registered;  
60 randomised
126 registered;  
66 randomised
AGITG and CTC 
icecreAm: Irinotecan cetuximab evaluation and cetuximab 
response evaluation among mutants
Patients with Kras-WT metastatic colorectal 
carcinoma or a G13D mutation
100 99
AGITG- and CTC-led international study 
impAct: Phase II trial using genomic sequencing and protein 
expression to direct first-line treatment 
Patients with metastatic pancreatic cancer 20 2
Garvan, AGITG, CTC and Sydney Catalyst
interAAct: phase II open-label trial comparing cisplatin plus 
5-fluorouracil versus carboplatin plus paclitaxel for anal cancer
Patients with locally recurrent or metastatic anal 
cancer
80 (int.) 0 (ANZ);  
36 (int.)
Cancer Research UK, AGITG and CTC study
topgeAr: Randomised phase II–III trial of preoperative 
chemoradiotherapy versus preoperative chemotherapy  
for gastric cancer
Patients with resectable gastric cancer suitable for 
these treatments
120 (stage 1);  
632 (stage 2)
120 (stage 1);  
118 (stage 2)
AGITG- and CTC-led international study 
32 
TRiAL PARTiCiPAnTS TARGeT ACCRuAL
Trials in follow-up
A la cArt: Australian phase III randomised trial of laparoscopy-
assisted resection compared with open resection
Patients with primary rectal cancer 470 475
AGITG and CTC study
AttAche: Timing of surgery and adjuvant chemotherapy for hepatic 
colorectal metastases
Patients with confirmed resectable liver 
metastases and no other disease
200 8
AGITG and CTC study
co.23: BBI608 and supportive care compared with placebo and 
supportive care for colorectal carcinoma 
Patients with advanced colorectal carcinoma 275 (ANZ);  
650 (int.)
78 (ANZ);  
282 (int.)
NCIC-CTG-led AGITG and CTC study
gAp: Phase 2 study of gemcitabine and nab-paclitaxel  
for pancreas cancer
Patients with resectable pancreas cancer 50 42
AGITG and CTC
petAcc 6: Addition of capecitabine to preoperative oxaliplatin 
chemoradiotherapy and postoperative oxaliplatin chemotherapy for 
rectal cancer (AG0707R)
Patients with locally advanced rectal cancer 135 (ANZ);  
1090 (int.)
127 (ANZ);  
1094 (int.)
EORTC (PETACC)-led, AGITG and CTC 
quasar 2: Phase III study of capecitabine and bevacizumab as 
adjuvant treatment of colorectal cancer (AG0107CR)
Patients with colon cancer treated by surgery 120 (ANZ);  
1892 (int.)
219 (ANZ);  
1952 (int.)
OCTO-led, AGITG and CTC 
register: Multicentre phase II study of risk evaluation in GIST with 
selective therapy escalation for response
Patients with gastrointestinal stromal tumour not 
suitable for curative surgery
80 47
AGITG- and CTC-led international study 
scot: Short-course oncology therapy, a study of adjuvant 
chemotherapy in colorectal cancer
Patients with fully resected stage III colorectal 
cancer
225 (ANZ):  
9500 (int.)
213 (ANZ);  
6144 (int.)
MRC-led, AGITG and CTC 
GYnAeCOLOGiCAL CAnCeR (COLLABORATinG WiTH AnZGOG)
Current trials
echo: Exercise during chemotherapy for ovarian cancer  
(ANZGOG 1304)
Women with newly diagnosed ovarian cancer 
starting treatment
500 11
ANZGOG and CTC study
outback: Phase III trial of addition of adjuvant chemotherapy to 
standard chemoradiation as primary treatment for cervical cancer 
(ANZGOG 0902)
Women with locally advanced cervical cancer 780 (int.) 136 (ANZ);  
682 (int.)
ANZGOG- and CTC-led international study
oVAr2.21: Noninferiority phase III trial of bevacizumab + 
gemcitabine and carboplatin compared with bevacizumab + 
doxorubicin and carboplatin
Women with recurrent cancer sensitive to 
platinum-based treatment
120 (ANZ);  
654 (int.)
76 (ANZ);  
682 (int.)
GCIG-led, ANZGOG and CTC study
pArAgon: Phase II study of anastrozole in gynaecological cancers 
(ANZGOG 0903)
Women with potentially hormone-responsive 
gynaecological cancers
 350 (int.) 208 (ANZ);  
315 (int.)
ANZGOG- and CTC-led international study
reZolVe: Phase II study to evaluate the safety and potential 
palliative benefit of intraperitoneal bevacizumab  
(ANZGOG 1101)
Women with symptomatic ascites due to 
advanced chemotherapy-resistant ovarian cancer
24 13
DGOG-led, ANZGOG and CTC 
Trials in follow-up
bnc105p phase i–ii combination study (ANZGOG 1103) 
ANZGOG- and CTC-led international study
Women with partly platinum-sensitive ovarian 
cancer in first or second relapse
Phase 1: up to 
24 (int.)
12 (ANZ);  
15 (int.)
gog182 
GOG-led, ANZGOG and CTC
Women with advanced stage (FIGO III-IV) 
epithelial ovarian or primary peritoneal 
carcinoma.
4200 (int.) 184 (ANZ),  
4312 (int.)
icon 6: Safety and efficacy of cediranib in combination with 
standard chemotherapy
Women with platinum-sensitive relapsed ovarian 
cancer
400 (int.) 17 (ANZ);  
486 (int.)
MRC-led, ANZGOG and CTC 
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icon 7: Randomised trial of adding bevacizumab to standard 
chemotherapy
Women with epithelial ovarian cancer who have 
not received systemic antitumour therapy
1444 (int.) 76 (ANZ);  
1450 (int.) 
icon 8: Dose-fractionated chemotherapy compared with 3-weekly 
chemotherapy for ovarian cancer
Women with ovarian, fallopian tube or primary 
peritoneal cancer.
145 (ANZ);  
1485 (int.)
70 (ANZ);  
1566 (int.)
MRC-led, ANZGOG and CTC 
oVAr 16: Pazopanib versus placebo for ovarian cancer 
AGO-led, ANZGOG and CTC
Women without disease progression after 
chemotherapy for epithelial ovarian, fallopian 
tube, or primary peritoneal cancer
900 (int.) 65 (ANZ);  
940 (int.)
portec 3: Chemo radiation and adjuvant chemotherapy compared 
with pelvic radiation alone in high-risk endometrial carcinoma
Women with advanced endometrial carcinoma 120 (ANZ);  
670 (int.)
122 (ANZ);  
688 (int.)
ANZGOG- and CTC-led international study
symptom benefit: Does palliative chemotherapy improve symptoms 
in women with recurrent ovarian cancer? (ANZGOG 0701)
Women with platinum-resistant or platinum-
refractory ovarian cancer
200 (ANZ);  
800 (int.)
143 (ANZ);  
948 (int.)
ANZGOG- and CTC-led international study
GeniTOuRinARY CAnCeR (COLLABORATinG WiTH AnZuP)
Current trials
bl 12: Phase II trial comparing nab-paclitaxel with paclitaxel  
ANZUP and CTC study
Patients with metastatic urinary tract cancer and 
previous platinum therapy
199 (ANZ) 9 (ANZ);  
101 (int.)
pain free trUs b: Phase III trial of methoxyflurane with periprostatic 
local anaesthesia to reduce discomfort of transrectal ultrasound-
guided prostate biopsy
Men scheduled to undergo first TRUS biopsy of 
the prostate 
420 (ANZ) 0
ANZUP and CTC study
bcg+mmc: Phase III trial of adding mitomycin C to BCG  
as adjuvant intravesical therapy for bladder cancer
Patients with high-risk, non-muscle-invasive 
bladder cancer
500 62
ANZUP and CTC study
enZAmet: phase III trial of enzalutamide in androgen-deprivation 
therapy for metastatic prostate cancer
Men with metastatic prostate cancer 1100 322 (ANZ):  
431 (int.)
ANZUP and CTC study
enZArAD: phase III trial of enzalutamide in androgen-deprivation 
therapy for localised prostate cancer
Men with high-risk localised prostate cancer 800 143 (ANZ);  
155 (int.)
ANZUP and CTC study
p3bep: Phase III trial of accelerated versus standard BEP  
(ANZUP 1302) 
ANZUP, ANZGOG and CTC study
Patients with intermediate and poor-risk 
metastatic germ-cell tumours
Stage 1:  
90 (ANZ);  
150 (int.)
Stage 2: 350
20 (int.)
Trials in follow-up
Accelerated bep: Feasibility study of accelerated BEP for advanced 
germ cell tumours
Patients with advanced germ cell tumours Up to 50 45
ANZUP and CTC study
chemo & cognition: Cognitive function and treatment for testicular 
cancer (ANZGCTG 0106)
Patients being treated and followed up for 
testicular cancer
154 151
ANZUP and CTC 
eversun: Phase II trial of everolimus alternating with sunitinib for 
renal cell carcinoma (ANZUP 0901)
Patients starting first-line systemic therapy for 
advanced renal cell carcinoma
55 56
ANZUP and CTC 
sorce: Adjuvant sorafenib for renal cell carcinoma (RE 05) 
MRC-led, ANZUP and CTC
Patients with resected renal cell carcinoma at 
intermediate or high risk of relapse
 250 (ANZ);  
1656 (int.)
168 (ANZ);  
1711 (int.)
LunG CAnCeR (COLLABORATinG WiTH ALTG)
Trial in start-up
niVorAD: Nivolumab and stereotactic radiotherapy  
versus nivolumab alone
Patients with advanced non-small- cell lung 
cancer progressing after chemotherapy
120 —
ALTG and CTC
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Current trial
br.31: Phase III study of adjuvant MEDI4736  
NCIC-led, ALTG and CTC
Patients with resected primary stage IB,  
IB (>4 cm), II or IIIA non-small-cell lung cancer
200 (ANZ); 
1100 (int.)
1 (ANZ);  
25 (int.)
BRAin CAnCeR (COLLABORATinG WiTH COGnO)
Trial in start-up
AceD: Phase II study of acetazolamide + dexamethasone  
v dexamethasone alone for cerebral oedema 
COGNO and CTC
Adults with recurrent or progressive high-grade 
glioma, who require dexamethasone or dose 
increase for cerebral oedema
84 —
Current trials
VertU: Veliparib, radiotherapy and temozolomide  
in unmethylated MGMT glioblastoma 
COGNO and CTC
Patients with newly diagnosed resected 
glioblastoma with unmethylated MGMT 
promoter gene
120 4
Trials in follow-up
cAtnon: Phase III trial of concurrent and adjuvant temozolomide 
chemotherapy for anaplastic glioma (EORTC 26053-22054)
Patients with non-1p/19q-deleted  
anaplastic glioma
100 (ANZ);  
748 (int.)
82 (ANZ);  
751 (int.)
EORTC-led, COGNO and CTC 
fUnDing
CTC undertakes investigator-initiated trials in collaboration with 
academic partners and clinical trial groups. Studies supported by 
research grants from industry are published independently of their 
funders in order to uphold CTC’s core commitment to integrity and 
transparency in research.
 Public grants for trials
 Pharmaceutical industry grants for trials
 Other public grants
 University infrastructure and  grants
 Consulting
 Interest and donations
 Other
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